Zhiyi Bio Completes Nearly RMB 100 Million Series C Initial Financing to Advance Phase III Clinical Pipeline

Guangzhou ZYBio Completes Nearly RMB 100 Million in First Tranche of Series C FinancingRecently, Guangzhou ZYBio completed the first tranche of its Series C financing, amounting to nearly RMB 100 million. The round was led by TECHNOLOGY FINANCIAL GROUP, with participation from Arie CAPITAL (NANJING) Investment Co., Ltd. The funds will be primarily used for the clinical development of the company’s new drug pipeline, particularly the Phase III clinical trials of SK08.

ZYBio is a China-based, globally oriented innovative drug R&D enterprise in the clinical development stage. As a leader in Live Biotherapeutic Products (LBPs) in China, ZYBio possesses a comprehensive technology and industrialization platform spanning from strain discovery to LBP development. The company’s independently developed SK08, which utilizes next-generation probiotics, is the most advanced LBP drug in China, with its Phase III clinical trial for IBS-D (Irritable Bowel Syndrome with Diarrhea) currently underway. Another proprietary candidate, SK10, indicated for chemotherapy-induced diarrhea, has completed its Phase I clinical trial in the United States.

TECHNOLOGY FINANCIAL GROUPStatement: Live biotherapeutic products (LBPs) represent an emerging frontier in drug development. Extensive clinical data have already demonstrated their safety and efficacy in treating gastrointestinal diseases, metabolic disorders, and tumors. Driven by strong market growth momentum, LBPs are poised to create a blue-ocean market valued at hundreds of billions. ZYBio has mastered core technologies across the entire LBP development lifecycle and possesses a comprehensive industrialization platform covering strain screening, functional evaluation, drug development, and manufacturing. We believe that ZYBio will continue to lead the advancement of live biotherapeutics in China, and we look forward to the early market launch of ZYBio’s SK08 to address the needs of more patients.

Arie InvestmentZYBio is a leading domestic player in live biotherapeutic products (LBPs), with its R&D progress ranking among the global first tier and possessing an independent, comprehensive industrialization platform. Its robust product pipeline, driven by actual clinical needs, demonstrates sustained growth potential and broad market prospects. We remain firmly optimistic about the future of this sector and ZYBio’s development potential.

Guangdong Technology Financial Group Co., Ltd. (hereinafter referred to as “Technology Financial Group”) is a state-owned enterprise authorized for operation by the People’s Government of Guangdong Province. As one of the earliest venture capital firms established in China and the first provincial-level technology finance group in the country, it is committed to building a key platform serving technological innovation in Guangdong. To date, the Group has a registered capital of RMB 10.6 billion and total assets of RMB 43.626 billion. The “Technology Financial” series of funds exceeds RMB 100 billion in scale, covering all 18 prefecture-level cities across the province. Its investments span 17 strategic industrial clusters throughout Guangdong, having provided financing and investment services to more than 3,000 technology enterprises and facilitated the initial public offerings (IPOs) of over 180 companies.